The iFat1 transgene permits conditional endogenous n-3 PUFA enrichment both in vitro and in vivo
Clarke, Shannon E.
Ma, David W. L.
MetadataShow full item record
CitationClarke, Shannon E., Jing X. Kang, and David W. L. Ma. 2014. “The iFat1 transgene permits conditional endogenous n-3 PUFA enrichment both in vitro and in vivo.” Transgenic Research 23 (1): 489-501. doi:10.1007/s11248-014-9788-x. http://dx.doi.org/10.1007/s11248-014-9788-x.
AbstractFat-1 transgenic mice, which endogenously convert n-6 PUFA to n-3 PUFA, are a useful tool in health research; however with this model timing of n-3 PUFA enrichment cannot be directly controlled. To add such capability, the novel Cre-recombinase inducible fat-1 (iFat1) transgenic mouse has been developed. The aim of this study was to characterize the utility of the iFat1 transgene as a model of Cre-inducible endogenous n-3 PUFA enrichment. Functionality of the iFat1 transgene was screened both in vitro and in vivo. In the presence of Cre, the iFat1 transgene resulted in a balancing (p < 0.01) of the n-6/n-3 PUFA ratio within phospholipids in the human embryonic kidney 293T cell line. For in vivo analysis, iFat1 transgenic mice were crossed with the R26-Cre-ERT2 (Tam-Cre) mouse line, a tamoxifen inducible Cre-expression model. Tam-Cre/iFat1 double hybrids were transiently treated with tamoxifen at 6–7 weeks, then terminated 3 weeks later. Tamoxifen treated mice had increased (p < 0.05) tissue n-3 PUFA and ≥two-fold reduction (p < 0.05) in the n-6/n-3 PUFA ratio of liver, kidney and muscle phospholipids relative to vehicle treated controls. Collectively these findings suggest that the iFat1 transgenic mouse may be a promising tool to help elucidate the temporal effects through which n-3 PUFA impacts health related outcomes.
Citable link to this pagehttp://nrs.harvard.edu/urn-3:HUL.InstRepos:12407039
- HMS Scholarly Articles